Thymic carcinoma medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(6 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Thymic carcinoma}}
{{Thymic carcinoma}}
{{CMG}}; {{AE}} {{AL}}
{{CMG}}; {{AE}} {{Marjan}}


==Overview==
==Overview==
The predominant therapy for thymic carcinoma is surgical resection. Adjunctive cisplatin-basedchemotherapy may be required.<ref name=age>National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.</ref>
The predominant therapy for thymic carcinoma is surgical resection. Adjunctive cisplatin-based chemotherapy may be required.<ref name=age>National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.</ref>
 
==Medical Therapy==
==Medical Therapy==
Treatment options for thymic carcinoma include the following:<ref name=age>National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.</ref>
Medical treatment options for thymic carcinoma include the following:<ref name=age>National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.</ref>
*Surgery
*CAP regimen (cyclophosphamide, doxorubicin, cisplatin): this is the first-line regimen
*Sunitinib<ref name="pmid25592632">{{cite journal| author=Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ et al.| title=Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. | journal=Lancet Oncol | year= 2015 | volume= 16 | issue= 2 | pages= 177-86 | pmid=25592632 | doi=10.1016/S1470-2045(14)71181-7 | pmc=4401497 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25592632  }} </ref>
*Gemcitabine
*Docetaxel
*Checkpoint inhibitors
*Radiation
*Radiation
Multimodality approach, such as:
Multimodality approach, such as:
Line 18: Line 23:


[[Category:Disease]]
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]
[[Category:Surgery]]

Latest revision as of 18:38, 10 September 2019

Thymic Carcinoma Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thymic carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Thymic carcinoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Thymic carcinoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thymic carcinoma medical therapy

CDC on Thymic carcinoma medical therapy

Thymic carcinoma medical therapy in the news

Blogs on Thymic carcinoma medical therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Thymic carcinoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

The predominant therapy for thymic carcinoma is surgical resection. Adjunctive cisplatin-based chemotherapy may be required.[1]

Medical Therapy

Medical treatment options for thymic carcinoma include the following:[1]

  • CAP regimen (cyclophosphamide, doxorubicin, cisplatin): this is the first-line regimen
  • Sunitinib[2]
  • Gemcitabine
  • Docetaxel
  • Checkpoint inhibitors
  • Radiation

Multimodality approach, such as:

  • Surgical resection
  • Radiation therapy
  • Cisplatin-based chemotherapy

References

  1. 1.0 1.1 National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.
  2. Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ; et al. (2015). "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial". Lancet Oncol. 16 (2): 177–86. doi:10.1016/S1470-2045(14)71181-7. PMC 4401497. PMID 25592632.